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Background: Programmed cell death ligand 1 (PD-L1) is a cell surface molecule that plays a critical role in suppressing
immune responses, mainly through binding of the PD-1 receptor on T lymphocytes. PD-L1 may be expressed by meta-
static melanoma (MM). However, its clinical and biological significance remains unclear. Here, we investigated whether
expression of PD-L1 in MM identifies a biologically more aggressive form of the disease, carrying prognostic relevance.
Patients and methods: PD-L1 expression was analyzed by immunohistochemistry using two different antibodies in
primary tumors and paired metastases from 81 melanoma patients treated at a single institution. Protein expression levels
were correlated with PD-L1 mRNA, BRAF mutational status and clinical outcome. PD-L1+ and PD-L1− subsets of the
A375 cell line were stabilized in vitro and compared using gene expression profiling and functional assays. Results were
confirmed using xenograft models.
Results: PD-L1 membrane positivity was detected in 30/81 (37%) of patients. By multivariate analysis, Breslow thick-
ness and PD-L1 membrane positivity were independent risk factors for melanoma-specific death {PD-L1 5% cutoff
[hazard ratio (HR) 3.92, confidence interval (CI) 95% 1.61–9.55 P < 0.003], PD-L1 as continuous variable (HR 1.03,
95% CI 1.02–1.04 P < 0.002)}. PD-L1 expression defined a subset of the BRAF-mutated A375 cell line characterized by
a highly invasive phenotype and by enhanced ability to grow in xenograft models.
Conclusions: PD-L1 is an independent prognostic marker in melanoma. If confirmed, our clinical and experimental data
suggest that PD-L1+ melanomas should be considered a disease subset with distinct genetic and morpho-phenotypic
features, leading to enhanced aggressiveness and invasiveness.
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introduction
In its early-stages melanoma can be cured by surgical resection,
but once it progresses to the metastatic stage it remains an in-
curable disease [1]. The finding of somatic mutations in the
BRAF oncogene in ∼40%–50% of melanoma patients [2, 3]
paved the way to the introduction of BRAF inhibitors (BRAFi)
as a standard treatment in locally advanced or metastatic
melanoma (MM) patients (MMP) with BRAFV600 mutation [4].
While clinical responses to BRAFi may be dramatic and some
patients treated with BRAF and MEK inhibitors (MEKi) may
stay in remission for years, the median duration of response is
7 months for patients treated with BRAFi alone and 11 months
for patients treated with BRAFi and MEKi. For this reason,
there is intense investigation into alternative or complementary
therapeutic strategies, including novel immunomodulatory
agents. Among these drugs, anti-PD-1 and anti-programmed
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cell death ligand 1 (PD-L1)-directed therapies show significant
clinical promises [5–7]. PD-L1/CD274 is one of the two ligands
for the T-cell inhibitory receptor PD-1 [8]. It may be expressed
on different cell types, including hematopoietic and epithelial
cells, and is upregulated in response to proinflammatory cyto-
kines, such as IFN-γ and IL-4 [9]. It may also be expressed by
tumor cells, as well as by non-neoplastic elements in the tumor
microenvironment [10–12]. In agreement with the proposed
function of the PD-1/PD-L1 axis in the induction and mainten-
ance of peripheral tolerance [11], surface expression of PD-L1
in some tumors has been reported to be an independent predict-
or of adverse clinical outcome [13]. Furthermore, expression of
the molecule appears to correlate with response to treatment, at
least in some tumor models [12].
In MM, PD-L1+ cells co-localize with tumor-infiltrating lym-
phocytes and IFN-γ production, suggesting that expression of
this molecule is part of the resistance strategy orchestrated by
the tumor against the host immune response [12]. However, the
prognostic significance of PD-L1 expression in melanoma
remains incompletely explored [14, 15].
By using qRT-PCR and immunohistochemistry, PD-L1 ex-
pression was evaluated in a longitudinal cohort of MMP. The
finding of a negative prognostic role for PD-L1 is backed by
in vitro data showing that the PD-L1+ fraction of the A375 mel-
anoma cell line may be considered distinctly a more aggressive
disease genetically, morphologically and phenotypically.
materials andmethods
patient characteristics
Cohort characteristics are reported in supplementary Materials and
Methods, available at Annals of Oncology online (Immunohistochemistry
(IHC), DNA extraction from formalin-fixed paraffin-embedded tissues
(FFPE), B-RAF mutation detection, mRNA extraction and detection by
quantitative and real time PCR). Detailed protocols are reported in supple-
mentary Materials and Methods, available at Annals of Oncology online.
cells and reagents
The cell lines and the antibodies used for this work are detailed in supple-
mentary Materials and Methods, available at Annals of Oncology online.
Induction of PD-L1/CD274 expression by lentiviral technology, flow
cytometry, western blot, confocal microscopy and in vitro assays.
Detailed protocols are reported in supplementary Materials and Methods,
available at Annals of Oncology online .
gene expression profiling and analysis
RNA extraction, labeling and analysis were carried out as detailed in supple-
mentary Materials and Methods, available at Annals of Oncology online.
xenograft models
Xenograft models are described in supplementary Materials and Methods,
available at Annals of Oncology online.
statistical analysis
Disease-free survival (DFS) was calculated as the time from first melanoma
diagnosis to first recurrence or death. Overall survival (OS) was calculated as
the time from first melanoma diagnosis to death. Cox proportional-hazards
models were used for univariate and multivariate analyses. Results are
expressed as hazard ratios (HRs) with 95% confidence intervals (95% CIs).
Additional statistical methods are delineated in supplementary Materials
and Methods, available at Annals of Oncology online.
results
PD-L1 expression in melanoma tissues
PD-L1 expression was studied by IHC in 81 consecutive, well
characterized MMP. PD-L1 expression was considered either as
a continuous or discontinuous variable using the 5% published
[16] or the 17.5% cutoff, determined here by recursive partition-
ing analysis (RPA), yielding comparable results.
In 73/81 MMP (90%), both ab58810 polyclonal (Abcam) and
5H1 monoclonal anti-PD-L1 antibodies were tested, showing a
high concordance rate (Cohen’s κ 72%, P < 0.0001). Representative
examples of PD-L1 immunostaining in melanoma tissues are
illustrated in Figure 1 and supplementary Figures S1–S4, avail-
able at Annals of Oncology online.
Complete clinico-pathological information of the antecedent
primary melanoma was available for 81 patients (supplementary
Table S1, available at Annals of Oncology online). No meaning-
ful associations were highlighted between PD-L1 expression and
the degree of tumor-infiltrating lymphocytes, scored according
to the current classification [brisk, non-brisk and absent (sup-
plementary Figures S2 and S3, available at Annals of Oncology
online)]. These results were consistent when PD-L1 was consid-
ered as continuous variable or with the 17.5% cutoff determined
by RPA. The frequencies of PD-L1 membrane immunohisto-
chemical positivity in paired primary and metastatic tumor
samples are reported in supplementary Table S4, available at
Annals of Oncology online. Overall, 40.3% of MM samples were
PD-L1+, when compared with 14% of primary melanomas
(P = 0.001, supplementary Table S5a and b, available at Annals
of Oncology online).
The PD-L1 positivity barely correlated with BRAF mutation,
although did not reach statistical significance (P = 0.051, supple-
mentary Table S6, available at Annals of Oncology online).
Lastly, PD-L1 mRNA levels did not correlate with membrane
protein expression in 34 samples analyzed (Cohen’s κ < 3%,
P = 0.4273, supplementary Table S7 and Figure S5, available at
Annals of Oncology online), suggesting that protein expression
must be used for diagnostic and prognostic purposes.
correlation between PD-L1 expression, DFS and OS
DFS was not significantly different between PD-L1+ and PD-
L1− lesions (Figure 2A and B), independently of the cutoff used.
As expected, well-established prognostic factors of the primary
melanoma, such as Breslow thickness [Breslow thickness 4.01–
6.0 versus ≤2: HR 2.91, 95% CI 1.18–7.21, P = 0.021], and ulcer-
ation [HR 2.26, 95% CI 1.19–4.31, P = 0.013], correlated with
DFS at multivariate analysis (supplementary Table S8, available
at Annals of Oncology online).
At a median follow-up of 147 months, the median OS for the
whole group of patients was 42 months. At the time of the ana-
lysis, 20 patients were still alive and 61 dead. At multivariate
analysis, PD-L1 membrane positivity was an independent risk
factors for melanoma-specific death [PD-L1 5% cutoff (HR 3.92,
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CI 95% 1.61–9.55, P < 0.003), PD-L1 as continuous variable
(HR 1.03, CI 95% 1.01–1.05, P < 0.002), supplementary Tables
S9 and S10, available at Annals of Oncology online, Figure 2C
and D]. On the contrary, median OS did not differ in patients
with cytoplasmic PD-L1− versus PD-L1+ lesions (16 versus 12
months, respectively, P = 0.1130).
Finally, by multivariate analysis, Breslow thickness, but not
ulceration, correlated with OS. Several reasons may justify these
results including: (i) the relative small sample size, (ii) the sub-
group comparisons, (iii) the influence of subsequent therapies
on patient outcome.
Thirty-four patients received a BRAFi at some point after
diagnosis of MM [25 treated with Vemurafenib (no restrictions
on prior therapy), 9 with Dabrafenib (patients had to have com-
pleted treatment or experienced treatment failure with at least
one prior standard systemic therapy)]. In the subgroup of
patients treated with BRAFi median OS was 16 months in
PD-L1− versus 9 in PD-L1+ melanomas (P = 0.0473).
When OS was analyzed as the time from diagnosis of metastat-
ic disease to death, membrane PD-L1 expression remained an in-
dependent prognostic factor as continuous variable or when a 5%
cut off was considered (supplementary Table S11, available at
Annals of Oncology online).
These results suggest that PD-L1 membrane expression is an
independent marker of unfavorable prognosis for MMP.
morphological features of PD-L1+ versus PD-L1−
A375 variants
In the second part of the work, we asked whether PD-L1 expres-
sion was simply the result of microenvironmental pressures on the
tumor cell or whether it was an intrinsic feature, marking a
disease subset with specific characteristics. After testing PD-L1 ex-
pression in a panel of melanoma cell lines, the A375 cell line
emerged as the only one with a constitutive PD-L1+ subpopulation
(supplementary Figure S6, available at Annals of Oncology online).
A375 variants homogeneously PD-L1+ and PD-L1− were sta-
bilized from the parental BRAF-mutated A375 cell line by
repeated cycles of immunomagnetic bead separation and cell
sorting (supplementary Figure S7A, available at Annals of
Oncology online).
PD-L1+ A375 cells grew loosely adherent to plastic and dis-
played an elongated shape, while the PD-L1− variant was made
of polygonal cells tightly adherent to plastic (supplementary
Figure S7B, available at Annals of Oncology online). The PD-L1−
variant was also infected with lentiviruses carrying PD-L1
A
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Figure 1. PD-L1 immunohistochemical expression using the mouse anti-human B7-H1 mAb (clone 5H1). (A) Staining of placental tissue, used as positive
control. (B) PD-L1-negative melanoma. (C–I) Examples of PD-L1 staining in melanoma tissues. Scattered PD-L1+ melanoma cells (C); focal and patchy PD-L1
staining (D); scattered melanoma cells showing PD-L1 expression and melanin granules (E); roundish aggregate of melanoma cells with moderate PD-L1 mem-
brane expression (F); strong PD-L1 immunostain in melanoma cells easily recognizable from intra and extracellular granular melanin depositions (G); (H–I)
staining of melanoma metastases. Note that cytoplasm of melanoma cells is pigmented due to abundant melanin deposition (original magnification ×40, scale
bar 50 μm).
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genetic material to express high levels of PD-L1 (PD-L1INF), but
these cells could not be distinguished from PD-L1− cells (supple-
mentary Figure S8, available at Annals of Oncology online).
When cultured in 3D, PD-L1+ A375 cells migrated through
matrigel and grew with a spindle cell morphology at the bottom
of the well. PD-L1− or PD-L1INF cells on the contrary formed
islet-like solid structures which did not leave matrigel (supple-
mentary Figure S7C, available at Annals of Oncology online). The
A375 unselected cell line behaved predominantly like the PD-
L1− variant, with a subpopulation of infiltrating PD-L1+ cells,
consistent with basal levels of PD-L1 expression (supplementary
Figure S7B and C, available at Annals of Oncology online).
These results suggest that PD-L1 expression defines a subset
of A375 cells characterized by a fibroblast-like morphology and
invasive properties. They also suggest that PD-L1 is a marker of
a more activated status of the melanoma cell line and not mech-
anistically responsible for the observed phenotype.
PDL-1+ A375 cells show a distinct gene profile with
upregulation of genes regulating tumor growth and
diffusion
Global gene expression profiles of PD-L1+ and PD-L1− A375
cells were then compared. In unsupervised hierarchical cluster-
ing analysis, the gene expression profiles of A375/PD-L1+ were
clearly distinguishable from those of PD-L1− replicates. The
characteristics of the genetic signature of PD-L1+ cells are
shown in Figure 3A and supplementary Table S12, available
at Annals of Oncology online. The genes most differentially
expressed by PD-L1+ cells are connected with activation/adhe-
sion/movement pathways (Figure 3A and B).
In a supervised analysis, a number of differentially expressed
genes connected with cell growth and invasion were selected.
Relevant examples of upmodulated genes include integrin α3
(ITGA3) and caveolin 1 (CAV1, Figure 3C). On the contrary,
genes connected with antigen presentation and immune
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Figure 2. Kaplan–Meier curves showing DFS and OS of MMP according to PD-L1 expression. (A) DFS according to membrane PD-L1 immunohistochemical
expression in melanoma tissues (cutoff 17.5%). (B) DFS according to membrane PD-L1 immunohistochemical expression in melanoma tissues (cutoff 5%).
(C) OS according to membrane PD-L1 immunohistochemical expression in melanoma tissues (cutoff 17.5%). (D) OS according to membrane PD-L1 immuno-
histochemical expression in melanoma tissues (cutoff 5%).
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response were downregulated, as highlighted by CD74 and HLA
Class II (HLA-DR, Figure 3C). Flow cytometric analyses con-
firmed a marked downregulation in the expression of HLAClass
II, CD74 and CD56 by PD-L1+ cells, while caveolin 1 protein
was increased (Figure 3D). All integrin α subunits were signifi-
cantly upregulated in A375 PD-L1+ variant, as confirmed by
western blot (Figure 3E) and confocal microscopy (Figure 3F),
indirectly supporting the morphologic observations and sug-
gesting that PD-L1+ cells may have a more aggressive behavior.
The arrays were validated at the protein level, confirming highly
significant results in PD-L1+ versus PD-L1− variants for the ex-
pression of MHC-Class II, CD74, CD56, caveolin 1 and
alpha1,3,5 integrins (supplementary Figure S9, available at
Annals of Oncology online).
PD-L1+ A375 cells show enhanced migration
and invasion in vitro
The enrichment in the expression of genes connected to migra-
tion and invasion in PD-L1+ A375 cells was then functionally
confirmed. Chemotaxis assays indicated that the PD-L1+ variant
migrated in a significantly more efficient way than the PD-L1−
variant, with the parental A375 cell line showing an intermedi-
ate behavior (Figure 4A). In line with the morphological data,
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Figure 3. PD-L1+ and PD-L1− A375 cells show different gene expression profiles. (A) Venn diagram showing 394 upregulated and 386 downregulated
sequences in PD-L1− compared with PD-L1+ A375 variants. (B) Functional annotations are reported in the pie chart and (C) most representative differentially
expressed genes are shown in a heat map. (D) Differential expression of HLA Class II, CD74, CD56 and caveolin 1 in PD-L1+ cells (full line) and PD-L1− cells
(dashed line) was confirmed by flow cytometry. Isotype control is shown as filled histogram. (E) Western blot and (F) confocal microscopy analyses of α integ-
rin subunits and caveolin 1 in PD-L1+ versus PD-L1− cell lines.
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infection of PD-L1 in A375 cells did not significantly modify
chemotaxis (supplementary Figure S8D, available at Annals of
Oncology online). Similar results were obtained when comparing
chemotaxis toward FCS (supplementary Figure S10, available at
Annals of Oncology online).
Wound-healing assays confirmed that the PD-L1+ cells were
able to migrate to the site of the wound with marked repair after
48 h, while the counterpart was significantly less efficient. As
observed above, A375 WT cells displayed an intermediate
ability to heal the wound (Figure 4B). PD-L1INF cells were not
significantly different from the WT counterpart (supplementary
Figure S8E, available at Annals of Oncology online).
PD-L1+ A375 cells show enhanced growth
and diffusion in vivo
The second set of genes that were up-regulated in the PD-L1+ A375
variant was connected to growth and activation. Consistently,
PD-L1+ A375 cells grew more than PD-L1− ones in 3D cultures.
PD-L1+ cells were characterized by a constitutively higher degree
of phosphorylation of the MAP kinases, including ERK1/2, p38
and JNK both in 2D (Figure 4C) and 3D cultures (supplemen-
tary Figure S11, available at Annals of Oncology online).
By using a xenograft model, we could confirm the increased
growth potential of PD-L1+ when compared with PD-L1− A375
cells. In these experiments, cells were injected subcutaneously
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into the right and left flank of NOD/SCID mice, respectively
and allowed to grow over a period of 2 weeks. Cells retained PD-
L1 expression after in vivo growth. In all instances, PD-L1+ cells
formed larger masses (Figure 4D), with signs of local infiltration
and showed a significantly higher expression of Ki-67 prolifer-
ation marker (Figure 4E).
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Figure 4. PD-L1+ cells display increased aggressiveness in vitro and in vivo. (A) Representative pictures (×20 magnification) of Boyden chamber filters stained
with hematoxylin/eosin showing increased invasion by PD-L1+ A375 cell variant, when compared with PD-L1−. Box plot on the right shows the absolute
numbers of cells in the lower side of the chamber filter after 72 h. Results are reported as mean ± SD (standard deviation) of four independent experiments.
(B) Representative pictures (×10 magnification) of a wound-healing assay at t = 0 h and after 48 h comparing PD-L1+ and PD-L1− A375 variants. Box plot
shows cell percentage of migration, determined by measuring wound widths ratio between the two time points. Values are representative of six independent
experiments ± SD. (C) Lysates from PD-L1− and PD-L1+ A375 variants were blotted for p-ERK, p-JNK and p-P38. Protein expression was normalized over the
corresponding unphosphorylated protein. Box plot shows the mean density ratio ± SD of four independent experiments. (D) Representative images from PD-
L1+ or PD-L1− in vivo tumors injected subcutaneously in NOD/SCID mice. Box plot in the middle shows the mean tumor volume of 6 experiments.
(E) Representative images from PD-L1− (upper panels) and PD-L1+ (lower panels) A375 xenografts stained with hematoxylin/eosin (left), PD-L1 (middle) and
Ki-67 (right) antibodies. The right panel in (D) shows a box plot with the mean % of Ki-67+ areas in PD-L1− and PD-L1+ tumors.
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Considered together, these results indicate that the PD-L1 ex-
pression marks a subset of the A375 cell line, which is intrinsic-
ally characterized by increased growth and motility.
discussion
This study shows that PD-L1 is an independent negative prog-
nostic factor in melanoma patients. This conclusion was
reached upon testing PD-L1 expression in a cohort of 81 con-
secutive MMP treated at a single institution, and comparing two
antibodies specific for PD-L1. In our series, the mouse mono-
clonal 5H1 antibody yielded the most reliable results. The
second indication is that PD-L1 cytoplasmic staining is not suit-
able for prognostic purposes. The third indication is that PD-L1
mRNA levels are not predictive of protein expression, in
agreement with previous studies [17]. The lack of correlation
between PD-L1 mRNA levels and protein expression may be
explained on the basis of two hypotheses: (i) PD-L1 expression
is controlled by posttranscriptional mechanisms, (ii) proinflam-
matory stimuli such as IFN-γ, IL-4 and GM-CSF are potent acti-
vators for inducing B7-H1 protein expression [9, 11].
In agreement with a negative prognostic role for PD-L1, our
study shows that MM express PD-L1 in significantly higher pro-
portions than primary lesions (40.3% versus 14%). In 17/22
patients, the metastatic site resulted positive while primary mela-
nomas were negative, suggesting that PD-L1 expression is
acquired during disease progression. PD-L1 expression has been
reported as neither a fixed characteristic of tumor cells, nor
homogeneously expressed. Hence, in 10 PD-L1− patients multiple
metastatic tumor samples from the same patient were analyzed,
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with concordant results. In two further PD-L1− patients that were
treated with a BRAFi, resistance acquisition was accompanied by
a transition of the lesion from PD-L1− to PD-L1+.
The second result of this work is that PD-L1 expression
appears to correlate with shorter OS during BRAFi treatment. If
confirmed in larger cohorts, this observation may be useful to
better stratify patients within clinical trials.
The impact of PD-L1 expression in terms of clinical behavior
was addressed by prior studies with controversial results, which
may be attributed partly to the absence of a validated staining
method and partly to the relatively small size of the cohorts
studied. While our study used a relatively large cohort and a
validated staining method, its main limitation is the retrospect-
ive nature, suggesting that these results should be confirmed
with a prospective study.
The functional significance of PD-L1 expression is classically
attributed to the inhibition of T cell responses, obtained
through binding of the PD-1 receptor [11]. Consistently, a
recent paper reported a positive correlation between PD-L1
expression by melanocytes and lymphocyte infiltration in both
nevi and melanomas, with PD-L1+ melanocytes, being frequent-
ly adjacent to infiltrating lymphocytes [12]. In our series and in
an additional independent cohort of 17 primary melanoma
samples, no significant association was observed between PD-L1
expression and the degree of TILs. It should be noted that, in
our series, most of patients received chemotherapy or BRAFi
while in the study reported by Taube et al. patients were receiv-
ing immunotherapy [12]. This suggests that the type of treat-
ment received should be considered when correlating PD-L1
expression with survival outcomes.
Nevertheless, the functional significance of constitutive and
targeted therapy-modulated PD-L1 expression has not been en-
tirely elucidated. A recent study evaluating PD-L1 expression in
a large panel of melanoma cell lines with or without exposure to
MAPK inhibitors showed that there is no association between
MAPK/PI3 K activation and PD-L1 expression, suggesting that
the constitutive PD-L1 expression or PD-L1 expression upon
alterations of signaling pathways, in the absence of a T-cell infil-
tration, may not serve as a biomarker [18].
Besides its role as an immunomodulatory molecule, recent
data in ovarian tumor models suggest that PD-L1 might per se
determine a more aggressive clinical course [19, 20]. To clarify
whether this may be confirmed in melanoma models, in the
second part of the paper, we explored the functional significance
of PD-L1 expression by melanoma cells. To do so, we used the
A375 line, which constitutively presents distinct PD-L1+ and a
PD-L1− subpopulations, a unique situation in the melanoma
lines tested. Stable PD-L1+ and PD-L1− variants of the A375 cell
line were thus stabilized and comparatively studied. Gene profil-
ing indicated that the PD-L1+ cell subset is characterized by a
unique genetic signature, with enhanced expression of genes con-
nected to growth, activation and invasion. A functional compari-
son confirmed that: (i) the PD-L1+ variant showed signs of
increased growth and invasion in vitro, (ii) these features were
enhanced when using 3D cultures and maintained after xeno-
grafting in immunocompromised mice. Forced expression of PD-
L1 molecules in the PD-L1- variant of the A375 line, however,
was not followed by the acquisition of increased growth and mo-
tility properties. This observation suggests that PD-L1 expression
might be a downstream marker of the activation of an oncogenic
pathway characterizing a genetically different cell subset, which
shows enrichment in genes that control cell differentiation and
movement. It also argues against a mechanistic involvement of
PD-L1 in determining increased aggressiveness of the disease.
In conclusion, from the clinical standpoint, the present results
suggest PD-L1 expression as a negative prognostic factor in mel-
anoma patients. From the translational standpoint, they indicate
that beside the known effects on immune response modulation,
PD-L1 expression marks a subset of melanoma cells character-
ized by a specific gene expression profile and by increased
growth and aggressiveness. Our results suggest that PD-L1 is
not mechanistically responsible for the more aggressive pheno-
type in melanoma cells. Future studies will tell whether PD-L1
expression is also a marker of resistance to selected therapies
and whether it may be successfully exploited alone or in com-
bination as a target for specific subsets of melanoma patients.
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